Small cap ASX shares have the potential to be able to grow quickly.

They’re starting from a smaller base and can have a much longer growth runway as they expand into new markets and hopefully grow profit margins.

These two businesses are demonstrating a lot of growth right now:

Audinate Group Ltd (ASX: AD8)

Audinate wants to pioneer the audio sector with its Dante audio-over-IPO networking solution, which it says is a world leader and used extensively in the professional live sound, commercial installation, broadcast, public address and record industries.

How does it work? Dante can replace the analogue audio cables by transmitting synchronised audio signals to multiple locations by using an ethernet cable.

The small cap ASX share recently revealed its FY21 third quarter which showed revenue growth of 31% to US$7 million.

Audinate explained that this latest quarter benefited from channel fill of newly released Bluetooth and USB-C AVIO adaptors, as well as an increase in orders from customers managing global supply chain concerns.

Compared to the first half of FY21, there has been continued strength of chips, cards and modules revenue.

However, there’s still potential supply chain problems. Audinate CEO Aidan Williams said:

We are closely watching global supply chains for potential negative impacts on both our customers and Audinate, which may constrain our near-term revenue and growth.

Along with our manufacturing and OEM partners, we are working to mitigate supply chain challenges and expect this near-term uncertainty to resolve itself as CY21 progresses. We remain very confident in the long-term outlook for the business.

Healthia Ltd (ASX: HLA)

Healthia is Australia’s largest allied health business and owns 30 brands. It operates across different sectors in healthcare – feet and ankles, bodies and minds, and eyes and ears.

It wants to deploy a minimum of $20 million of capital each year to buy now allied health business acquisitions. Healthia has successfully grown to the size it is through acquisitions, as well as organic growth.

The small cap ASX share is working on new business opportunities through cross-referrals between Healthia’s businesses to promote better patient outcomes. It also wants to provide clinicians with industry leading education, tools and support and continue to develop industry leading career opportunities for all team members. This is expected to continue to drive strong organic performance into the future.

In the FY21 half-year result, Healthia generated organic revenue growth of 14.5%, though total revenue went up 38.9%. Underlying earnings before interest, tax, depreciation and amortisation (EBITDA) grew 90.7% to $11 million, partly thanks to the underlying EBITDA margin rising 486 basis points to 17.87%. Underlying earnings per share (EPS) grew by 78.2% to 6.86 cents.

The board are confident on the balance sheet, which is why the business is now paying a dividend. The interim dividend payment to shareholders was 2 cents per share.

More reading

• 3 growing small cap ASX shares to watch
• Brokers name 3 ASX shares to buy now
• Audinate (ASX:AD8) share price climbs on Q3 update
• 2 fantastic ASX shares that brokers rate as buys
• 3 growing small cap ASX tech shares to watch

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended AUDINATEGL FPO. The Motley Fool Australia has recommended HEALTHIA FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post 2 small cap ASX shares that are growing quickly appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3etBBPL

Advanced Human Imaging Ltd (ASX: AHI) shares have been up and down today following news of a signed marketing agreement. The Advanced Human Imaging share price opened slightly higher following the news before slumping 3.35% to $1.73. 

However, at the time of writing, the company’s shares have recovered to trade at $1.82, up 1.68% for the day so far.

What did Advanced Human Imaging announce?

Advanced Human Imaging shares are on a rollercoaster today after the company advised it has entered into a marketing agreement with China-Based, Tinjoy Biotech (Tinjoy).

The partnership will see Advanced Human Imaging’s CompleteScan product integrate with Tinjoy’s WinScan app in China. Launch of the combined offering is being targeted for July 2021.

Brought to market in 2020, Tinjoy’s WinScan app services roughly 28 million consumers every month in China. The digital health platform specialises in multiple segments of personal and population health as well as medical and preventative care. The company uses data analytics for the early detection and health assessment of individuals at risk of chronic disease.

Under the terms of the binding sheet, Advanced Human Imaging will contribute US$200,000 over three tranches. The funds will be used towards the training of 500 call centre team members to sell the CompleteScan integration. In addition, the remaining monies will be allocated towards material production and the launch of the CompleteScan integrated WinScan app.

Advanced Human Imaging is hoping to achieve 1 million active monthly users within the first year of the signed agreement.

Judging by today’s Advanced Human Imaging share price moves, it seems investors have mixed feelings over the significance of the company’s news.

What did management say?

Vlado Bosanac, chair and CEO of Advanced Human Imaging, commented:

Our teams have been in constant communications over the last 8 weeks progressing the application integration points. We are fortunate to have mandarin speaking staff that are able to navigate the language barrier seamlessly…

The sheer size of the population and the high level of mobile device usage in China, gives me tremendous confidence in the acceptance of our unique and easy to use technology. I believe this will culminate in a very successful partnership.

About the Advanced Human Imaging share price

Including today’s gains, the Advanced Human Imaging share price has rallied by around 1,000% over the last 12 months. The company’s shares are, however, still sitting below their 52-week high of $2.19 reached in March this year.

Advanced Human Imaging has a market capitalisation of around $238 million.

More reading

• What’s with the Advanced Human Imaging (ASX:AHI) share price today?
• Why has the Advanced Human Imaging (ASX:AHI) share price plunged 5%?

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Advanced Human Imaging (ASX:AHI) share price wobbles on agreement appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2Qpw0SC

The Peninsula Energy Ltd (ASX: PEN) share price has jumped 4% higher in morning trade to 13 cents apiece. Investors are watching the company’s share price after the uranium miner released its quarterly report.

Let’s take a look at how Peninsula performed for the last quarter.

Peninsula releases quarterly activities report

Earlier today, Peninsula released its quarterly activities report for the March quarter.

The company reported an operating cash loss of US$2.2 million for the quarter with no sales recorded.  For the 9 months to 31 March, Peninsula noted an operating cash loss of US$5.7 million on sales of US$3.4 million.

For the March quarter, Peninsula highlighted US$6.8 million cash on hand. In addition, the company also provided a summary of its purchase agreements. For the calendar year of 2022, Peninsula noted that it has entered into binding contracts for the delivery of 450,000 pounds of uranium. As a result, Peninsula forecasts a net cash margin of US$8 million to US$9 million in 2022.

Peninsula also highlighted the company’s upgrade to the OTCQB Venture Market earlier this year.

More on the Peninsula share price

Peninsula is an ASX-listed uranium mining company. The company’s flagship Lance Project located in Wyoming, USA is the only US-based uranium project using a low pH, in-situ recovery (ISR).

In order to ‘decarbonise’ the country’s power sector, the US Department of Energy has allocated US$75 million towards the establishment of a national strategic uranium reserve. As a result, Peninsula is in a position to potentially benefit from various initiatives of the US government.

The Peninsula share price bolted out of the blocks in 2021, hitting 18 cents in mid-February. After dipping since then, the company’s share price has struggled to gain traction. Shares in Peninsula were given a boost earlier this month after the company delivered favourable results from field demonstration tests at its Lance Project. However, despite the slew of updates the Peninsula share price has tanked more than 20% in the past 12 months.

As highlighted before, shares in Peninsula Energy were upgraded to the middle tier of the OTC market earlier this year. The upgrade was in response to strong trading volumes and provides overseas investors greater access to securities in Peninsula Energy.

More reading

• Why the Peninsula Energy (ASX:PEN) share price is soaring 9%

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Peninsula (ASX: PEN) share price jumps on update appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3vjQ1Zv

In early afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week on a subdued note. At the time of writing, the benchmark index is down 0.1% to 7,050.8 points.

Four ASX shares that are not letting that hold them back are listed below. Here’s why they are charging higher:

Doctor Care Anywhere Group PLC (ASX: DOC)

The Doctor Care Anywhere share price is up almost 4% to $1.07. This follows the release of the telehealth company’s first quarter update. For the three months ended 31 March, Doctor Care Anywhere reported a 16.5% increase in unaudited underlying revenue to 4.4 million pounds (A$6.87 million). This was driven partly by a 14.7% increase in sign-ups to the platform to 500,000 and a 21.9% increase in consultations delivered to 90,500.

Next Science Ltd (ASX: NXS)

The Next Science share price has rocketed 25% higher to $1.78. Investors have been fighting to get hold of the medical device company’s shares after the US FDA approved its XPerience No Rinse Antimicrobial Solution. The XPerience product is inserted into a surgical site, which is then closed, to fight infection for up to several hours afterwards. Management believes the product can be used in every open surgery.

NIB Holdings Limited (ASX: NHF)

The NIB share price is up 10% to $5.91 after providing guidance for FY 2021. According to its trading update, the private health insurer has been performing positively during the second half. As a result, it expects to report underlying operating profit of $200 million to $225 million in FY 2021. This will be a big lift from the first half, when it posted underlying operating profit of $86.9 million.

Talga Group Ltd (ASX: TLG)

The Talga share price has jumped 25% to $1.71. This appears to be a delayed reaction to the company providing an update on its electric vehicle anode (EVA) qualification plant last week. According to the release, designs for the plant have been finalised and engineering work is progressing well. Talga has now placed orders for materials and equipment and hopes to commence its EVA plant’s installation in the fourth quarter of 2021.

More reading

• ASX 200 flat: NIB update impresses, Altium upgraded
• Doctor Care Anywhere (ASX:DOC) share price lifts on upbeat update
• Why the Next Science (ASX:NXS) share price opened 40% higher
• NIB (ASX:NHF) share price on watch following business update
• Why GPT, Mayne Pharma, Talga, & Zip shares are tumbling lower

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Doctor Care Anywhere Group PLC. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Nexus Energy Limited. The Motley Fool Australia has recommended Doctor Care Anywhere Group PLC and NIB Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why Doctor Care Anywhere, Next Science, NIB, & Talga are charging higher appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3ezxTnJ

ASX e-commerce shares are being shot down left, right, and centre after COVID-19 created unrealistic earnings expectations for FY21.

The Kogan.com Ltd (ASX: KGN) share price joins its embattled peers Redbubble Ltd (ASX: RBL) and Temple & Webster Group Ltd (ASX: TPW) in the bargain bin after falling 20% last week.

With the Kogan share price falling almost 50% year-to-date to 11-month lows of $10.30, this broker has made the bold call to buy the dip. 

Why did Kogan fall off a cliff?

Kogan’s update reflects the broader ongoing reversal of supercharged COVID-19 driven earnings. Morgans has described what the market is currently witnessing as a cycle of tough comparisons to periods with COVID-19 tailwinds and “unlikely to be repeated” sales. 

Kogan’s update looked promising at face value but revealed that earnings before interest, tax, depreciation and amortisation (EBITDA) fell more than 24% compared to the prior corresponding period.

As a result of lower customer demand, the company will have to store larger than expected levels of inventory, which could potentially lead to weaker margins in the near term. 

Credit Suisse rates the Kogan share price as outperform 

Credit Suisse believes the ongoing difficulties associated with stock levels returning to normal and cycling of strong sales growth is only temporary. Looking past the near-term slowdown, the broker is positive on Kogan’s medium-term outlook and opportunities. 

Credit Suisse observed that the number of active customers continues to expand, but sales momentum appears to have slowed at a faster rate than expected. The broker retained an outperform rating and reduced its target price from $20.85 to $17.93.  

With the Kogan share price fetching $10.30 at the time of writing, this represents a significant upside of 69%. 

Foolish takeaway

While Credit Suisse has put forth an eye-watering 69% upside to the Kogan share price, investors should also remember the risks of trying to ‘catch the knife’. 

Shares such as the A2 Milk Company Ltd (ASX: A2M) and AGL Energy Ltd (ASX: AGL) are classic examples of seemingly quality shares that have dipped lower and lower. 

More reading

• Leading brokers name 3 ASX shares to buy today
• AGL Energy (ASX:AGL) share price hits 52-week low
• 2 ASX shares that could be dividend stars of the future
• Top brokers name 3 ASX shares to buy next week
• Top brokers name 3 ASX shares to sell next week

Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Kogan.com ltd and Temple & Webster Group Ltd. The Motley Fool Australia owns shares of and has recommended A2 Milk. The Motley Fool Australia has recommended Kogan.com ltd and Temple & Webster Group Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post This broker thinks you should buy the Kogan (ASX:KGN) share price dip appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2QoCZLC

The Commonwealth Bank of Australia (ASX: CBA) share price has been making investors very happy over the past 12 months. The ASX’s largest bank has grown more than 52% in value over the past year, including a healthy 7% in 2021 so far.

On Friday, CBA broke its 52-week high and closed at its highest level since February 2020 when the bank hit its pre-COVID all-time high.

Today, CBA has climbed even higher, making a fresh new 52-week high of $89.99 this morning. While that share price is laughably tantalising for being so close to $90, let’s take a look at what this ASX bank has to offer at ~$90 a share today.

What does Commonwealth Bank offer today?

So, at the current share price, CBA is trading with a market capitalisation of $159.2 billion, a price-to-earnings (P/E) ratio of 19.96 and a trailing dividend yield of 2.76%.

At this market capitalisation, CBA is now back atop its sometimes-occupied throne of the most valuable company on the S&P/ASX 200 Index (ASX: XJO). Yes, CBA is now the biggest public company in Australia, a position it has regularly shared with BHP Group Ltd (ASX: BHP) and CSL Limited (ASX: CSL) over the past few years.

So at a P/E ratio of 19.96, CBA is still below the current average for an ASX 200 company, which is 23.65. However, it is also below the average P/E of other big ASX banks today. To illustrate, let’s take a look at CBA’s big four brethren.

Westpac Banking Corp (ASX: WBC) shares are currently trading on a sky-high P/E ratio of 39.63. But National Australia Bank Ltd (ASX: NAB) and Australia and New Zealand Banking Group Ltd (ASX: ANZ) currently have P/Es of 24.67 and 23.79 respectively.

Turning to dividend yields, and CBA is once again looking competitive. A trailing yield of 2.76% far outstrips ANZ’s current trailing yield of 2.08% on current pricing. Ditto with NAB’s 2.24%. And Westpac is currently offering investors just 1.23%.

However, it’s worth noting that the dividends we will see over the rest of 2021 are likely to look a lot different to what we have seen over 2020.

So CBA looks objectively attractive on all of these metrics compared to its ASX banking stablemates. But that doesn’t automatically mean CBA shares are a buy today. So what’s the 411?

Is the CBA share price a buy today?

According to CommSec, broker Goldman Sachs has a ‘sell’ rating on CBA shares, with a 12-month price target of $73.64 a share. The investment bank and broker points to CBA’s heavy exposure to the retail housing market as the primary reason it is not too keen on CBA shares at $90.

More reading

• Westpac (ASX:WBC) share price higher despite $282 million profit hit
• CommBank (ASX:CBA) share price hits new 52-week high
• 2 ASX dividend shares with very generous yields
• Is the CBA (ASX:CBA) share price a buy for a recovery of dividends?
• Top brokers name 3 ASX shares to sell next week

Sebastian Bowen owns shares of National Australia Bank Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Is the Commonwealth Bank (ASX:CBA) share price a buy at $90? appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2QVL3TZ

At lunch on Monday the S&P/ASX 200 Index (ASX: XJO) is trading broadly flat. The benchmark index is currently down a few points to 7,058.4 points.

Here’s what is happening on the market today:

NIB update impresses

The NIB Holdings Limited (ASX: NHF) share price is surging higher following the release of a trading update. According to the release, for the nine months ending 31 March 2021, NIB reported that its business was performing well despite the ongoing uncertainty surrounding the COVID-19 pandemic. As a result, it expects underlying operating profit to come in at $200 million and $225 million in FY 2021. During the first half, its underlying operating profit was $86.9 million.

Altium shares upgraded

The Altium Limited (ASX: ALU) share price is trading flat on Monday despite being upgraded by a leading broker. According to a note out of Shaw & Partners, its analysts have upgraded the company’s shares to a buy rating with a $34.00 price target. The broker believes that Altium is well-placed to benefit from the global economic recovery and expects its revenue to hit an inflection point in FY 2021.

Perenti rises

The Perenti Global Ltd (ASX: PRN) share price is pushing higher today. This follows the receipt of a letter of intent from Newcrest Mining Ltd (ASX: NCM) for works at the gold miner’s Red Chris Project. Should everything go ahead as planned, the company advised that it anticipates the project will generate revenue of $38 million over a 16-month period.

Best and worst ASX 200 performers

The NIB share price is the best performer on the ASX 200 on Monday by some distance with an 11% gain following its update. The worst performer has been the Whitehaven Coal Ltd (ASX: WHC) share price with a decline of almost 6%. This coal miner’s shares have come under pressure recently amid concerns over issues at its Narrabri operation.

More reading

• Perenti (ASX:PRN) share price climbs on North American expansion plans
• This broker just upgraded the Altium (ASX:ALU) share price to a buy
• NIB (ASX:NHF) share price on watch following business update
• 5 things to watch on the ASX 200 on Monday
• 2 excellent ASX 200 blue chip shares to buy

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends Altium. The Motley Fool Australia owns shares of Altium. The Motley Fool Australia has recommended NIB Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post ASX 200 flat: NIB update impresses, Altium upgraded appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/32KNiMv

The Universal Biosensors Inc (ASX: UBI) share price is edging lower today. As of writing, shares in the medical diagnostics company are trading for 73 cents each, down 1.3%. By comparison, the S&P/ASX All Ordinaries Index (ASX: XAO) is 0.02% lower.

Today’s price movement comes after the company announced another deal to distribute one of its products – this one in South Africa.

Let’s take a closer look at today’s news and what it means for the Universal Biosensors share price.

What’s up with the Universal Biosensors share price?

In a statement to the ASX, Universal Biosensors advised it has entered a nonexclusive agreement with Vicard SA for the distribution of its wine testing platform device, Sentia, in South Africa. The deal is for 3 years.

Vicard SA is an importer of products necessary for wine production into South Africa. It has been in operation for more than 20 years.

This is the third such deal for the Sentia product. The company recently announced distribution deals in Chile and the United States. The Universal Biosensors share price rose 6% on the former deal and fell on the latter.

Sentia is a portable, wine-testing device that delivers results in less than 60 seconds. The test measures the amount of free sulphur dioxide present in a wine product. Free sulphur dioxide needs to be present in wine for bacterial stability.

Management commentary

Universal Biosensors CEO John Sharman said:

Securing distribution in South Africa is another step forward in the commercialisation of Sentia globally. Vicard SA has 20 years of experience supplying high quality resources to the South African wine industry and there are 500 wineries which will now have the opportunity to experience Sentia.

Along with the current capability we believe the possibility of Sentia’s future testing capability for glucose, fructose, malic acid and others will add significant value to the winemaking industry. We are negotiating terms with a number of key industry players around the world and look forward to reporting additional distribution partnerships in due course.

Vicard SA CEO Michael Fernandez added:

I am thrilled to be bringing Sentia to the South African wine industry. The initial reaction from my customers has been very positive and they understand the unique benefits the system offers.

Universal Biosensors share price

Over the past 12 months, the Universal Biosensors share price has increased 279%. In fact, just over the last month, the company’s value has appreciated 28.6%. On 9 April, the share price went up 36% in one day after a medical-related update.

The Universal Biosensors share price has a market capitalisation of $127.8 million.

More reading

• Universal Biosensors (ASX:UBI) share price sinks despite new deal
• Why the Universal Biosensors (ASX:UBI) share price is up 6% today
• Here’s why the Universal Biosensors (ASX:UBI) share price is soaring 10%
• Why the Universal Biosensors (ASX:UBI) share price is shooting 36% higher today
• Universal Biosensors (ASX:UBI) share price is lifting today. Here’s why

Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Universal Biosensors (ASX:UBI) share price dips despite latest update appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/32P6BV0

The Archer Materials Limited (ASX: AXE) share price is climbing after news the company has secured access to the infrastructure it needs to continue developing its biochip.

The company’s new access to world-class facilities means it can continue working towards biochip feature sizes of less than 10-nanometres.

At the time of writing, the Archer Materials share price is up 3.5%, trading for 89 cents.

Let’s take a closer look at the news out of the materials technology developing company today.

Next step towards a 10-nanometre biochip

Today, Archer announced it has access to some of the rare instruments and facilities able to work on nanoscale devices. As a result, the company can begin scaling down its biochip technology to 10 billionths of a metre (10-nanometres (nm)).

The company’s biochip is a lab-on-chip device. It allows medical laboratory tests on an integrated circuit and includes multiple functional areas and componentry. It also includes microfluidic channels and active biosensing areas.

Replicating the abilities of the Biochip on a scale of less than 10nm would place Archer’s technology as the global best-in-class in the semiconductor industry, the company has said previously.

Archer’s access to a suite of deep tech infrastructure resources adds to its access to a $150 million research and prototype semiconductor foundry where it fabricates its devices.

Commentary from management

Archer CEO Dr Mohammad Choucair welcomed the news, saying:

We are very pleased to secure access to world-class facilities that would otherwise be extremely costly to purchase and operate ourselves.

Archer’s growth has involved integrating the company’s early-stage tech development within institutional scale operations, and this ultimately translates to maintaining a strong cash position and no corporate debt.

Archer Materials share price snapshot

The Archer Materials share price is having a fantastic year on the ASX.

Currently, the Archer Materials share price is up 71% year to date. It’s also up 423% over the last 12 months.

The company has a market capitalisation of around $194 million, with approximately 226 million shares outstanding.

More reading

• Archer (ASX:AXE) share price retreats despite positive update

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Here’s why the Archer Materials (ASX:AXE) share price is up today appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3tRhv8l

The Perenti Global Ltd (ASX: PRN) share price is on the rise in morning trade. This comes after the company announced it has received a lucrative opportunity to expand its North American presence.

At the time of writing, the mining services company’s shares are fetching $1.13, up 4.15%.

Continued North America expansion

Perenti shares are in the green today after investors digest the company’s latest positive announcement.

In today’s release, Perenti advised its subsidiary, Barminco, has received a letter of intent from Newcrest Mining Ltd (ASX: NCM) for works at the Red Chris Project.

Located around 80 kilometres south of Dease Lake in northwest British Columbia, Canada, the Red Chris Project is a copper-gold mine. In 2019, Newcrest acquired a 70% interest in the Red Chris Project, in a joint venture with Imperial Metals.

Under the proposed agreement, Barminco will conduct a number of services for the development of an underground exploration decline. These include mobilisation and site establishment activities and development to build a 3.5-kilometre decline.

Essentially, a decline is an underground system of ramps and horizontal crosscuts that connects access points targeting specific mineralised areas. However, Newcrest will also use the decline to support access to extend the operation of the open pit.

It is expected that both parties will come together in the coming weeks to formally sign off on the first stage of works. Commencement of ground activities is scheduled for mid-2021.

The Perenti share price is responding positively after the company advised it anticipates the project will generate revenue of $38 million over the 16-month period.

Management commentary

Perenti managing director and CEO Mark Norwell touched on the exciting development, saying:

Geographic expansion has been a key focus of our 2025 strategy and this early-stage work at Red Chris builds on our regional growth capabilities after commencing in North America just over a year ago.

The underground exploration decline works are a significant opportunity and puts the Company in a strong position to access the much wider scope of works associated with the potential block cave development that Newcrest aims to progress towards in the coming years.

This project fits with our strategy as we continue to pursue high quality growth opportunities within attractive mining jurisdictions, partnering with top-tier producers holding multi-mine portfolios and long-life, expandable assets.

Perenti share price summary

The Perenti share price has gained around 41% over the past year but is down 20% year to date. The company’s shares have been on a steep decline since mid-February following the release of its half-year results.

Perenti has a market capitalisation of roughly $758 million, with more than 704 million shares outstanding.

More reading

• 5 things to watch on the ASX 200 on Monday
• 5 things to watch on the ASX 200 on Friday
• 5 things to watch on the ASX 200 on Thursday
• 5 things to watch on the ASX 200 on Wednesday
• ASX miners in focus as the copper price looks poised to crack above 10-year highs

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Perenti (ASX:PRN) share price climbs on North American expansion plans appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3njqBbu